Felbamate in refractory partial epilepsy.

Abstract

This open-label study was performed to evaluate efficacy and safety of Felbamate (FBM) add-on therapy in drug-refractory partial epilepsy. We evaluated 36 patients (12 males) aged 11-68 years (mean 29.8) in which FBM was titrated gradually from 300 mg/day to a mean total maintenance daily dose of 1936 mg. Patients were monitored according to clinical practice and performed regularly laboratory tests. Mean follow-up of FBM therapy was 10 months (range 2-27). In this study, 5% of patients resulted to be seizure-free, 11% showed a seizure reduction more than 75%, 23% decreased their seizure frequency between 50% and 75% (P = 0.0001). The adverse events which were reported more frequently were: nausea, vomiting, anorexia and weight loss. Even if the patients sample is small FBM proves its efficacy in partial epilepsy, showing a relatively well tolerated profile.

• Authors: R Canger, A Vignoli, R Bonardi, L Guidolin
• Journal: Epilepsy research (Epilepsy Res) Vol. 34 Issue 1 Pg. 43-8 (Mar 1999) ISSN: 0920-1211 [Print] Netherlands
• PMID: 10194111 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Anticonvulsants
• Phenylcarbamates
• Propylene Glycols
• Felbamate

Topics

• Adolescent
• Adult
• Aged
• Anticonvulsants (adverse effects, therapeutic use)
• Child
• Drug Resistance
• Drug Therapy, Combination
• Epilepsies, Partial (drug therapy)
• Felbamate
• Female
• Humans
• Male
• Middle Aged
• Phenylcarbamates
• Propylene Glycols (adverse effects, therapeutic use)
• Treatment Outcome